



## (51) International Patent Classification:

A61K 39/395 (2006.01) C07K 17/14 (2006.01)  
C07K 16/28 (2006.01)

## (21) International Application Number:

PCT/US2014/051790

## (22) International Filing Date:

20 August 2014 (20.08.2014)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

|            |                               |    |
|------------|-------------------------------|----|
| 61/869,510 | 23 August 2013 (23.08.2013)   | US |
| 61/907,749 | 22 November 2013 (22.11.2013) | US |
| 13198784   | 20 December 2013 (20.12.2013) | EP |
| 61/990,475 | 8 May 2014 (08.05.2014)       | US |

## (71) Applicant: MACROGENICS, INC. [US/US]; 9640 Medical Center Drive, Rockville, MD 20850 (US).

## (72) Inventors: BONVINI, Ezio; 11136 Powder Horn Drive, Potomac, MD 20854 (US). JOHNSON, Leslie, S.; 14411 Poplar Hill Road, Darnestown, MD 20874 (US). HUANG, Ling; 8210 Moorland Lane, Bethesda, MD 20818 (US).

MOORE, Paul, A.; 7013 Old Gate Road, Bethesda, MD 20878 (US). CHICHILI, Gurunadh, Reddy; 13926 Lullaby Road, Germantown, MD 20874 (US). ALDERSON, Ralph, Froman; 13601 Query Mill Road, North Potomac, MD 20878 (US).

## (74) Agents: AUERBACH, Jeffrey, I. et al.; AuerbachSchrot LLC, 2200 Research Blvd., Suite 560, Rockville, MD 20850 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

[Continued on next page]

## (54) Title: BI-SPECIFIC MONOVALENT DIABODIES THAT ARE CAPABLE OF BINDING CD123 AND CD3, AND USES THEREOF




Figure 3A

(57) Abstract: The present invention is directed to sequence-optimized CD 123 x CD3 bi-specific monovalent diabodies that are capable of simultaneous binding to CD 123 and CD3, and to the uses of such diabodies in the treatment of hematologic malignancies.



GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*